Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: sa...
October 3, 2026
Share
Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.